11. CASE REPORT: CUTANEOUS LEUKOCYTOCLASTIC VASCULITIS DUE TO ANTI-TUBERCULOSIS MEDICATIONS AT NATIONAL LUNG HOSPITAL IN 2023
Main Article Content
Abstract
Introduction: Anti-tuberculosis drug-associated cutaneous adverse reactions are common in the treatment of tuberculosis. Cutaneous adverse reactions commonly encountered include: Morbilliform rash, exfoliative dermatitis, urticaria, psoriasiform drug eruption, lichenoid eruption, toxic epidermal necrolysis, Stevens-Johnson syndrome... However, cutaneous leukocytoclastic vasculitis (LCV) due to anti-tuberculosis medications is a rare adverse reaction.
Objective: This article aims to report a case of cutaneous LCV due to anti-tuberculosis medications. The primary goals include contributing to scientific data, as well as sharing insights into the diagnostic and treatment processes.
Case report: We describe a 70-year-old male diagnosed with pulmonary tuberculosis, treated with a regimen including rifampicin, isoniazid, pyrazinamide, and ethambutol. After 1 months of treatment, the patient developed multiple purpuric papules in the extremities. Histopathological results from skin biopsy were consistent with leukocytoclastic vasculitis. The skin lesions gradually resolved after discontinuation of tuberculosis medications and treatment with corticosteroids and antihistamines. Each tuberculosis medication was reintroduced every 4 days. Purpuric papules recurred when the patient rechallenged pyrazinamide at a dose of 500 mg and after that, rifampicin at a dose of 450 mg.
Discussion: The discussion focuses on the epidemiology, the etiology and the treatment of LCV. In this case, we report about how we can diagnose LCV in this case by pathology and provocation test.
Conclusion: This is a rare case of cutaneous leukocytoclastic vasculitis due to rifampicin and pyrazinamide.
Article Details
Keywords
Cutaneous leukocytoclastic vasculitis; rifampicin; pyrazinamid; pulmonary tuberculosis.
References
vasculitis, Histopathology, 56(1), 2010,p. 3-23.
[2] G Haugeberg, R Bie, A Bendvold et al., Primary
vasculitis in a Norwegian community hospital:
A retrospective study, Clin Rheumatol, 17(5),
1998, p. 364-8.
[3] A Arora, DA Wetter, TM Gonzalez-Santiago
et al., Incidence of leukocytoclastic vasculitis, 1996
to 2010: A population-based study in
Olmsted County, Minnesota, Mayo Clin Proc,
89(11), 2014, p. 1515-24.
[4] GL Fekete, L Fekete, Cutaneous leukocytoclastic
vasculitis associated with erlotinib treatment:
A case report and review of the literature, Exp
Ther Med, 17(2), 2019, p. 1128-1131.
[5] X Li, J Xia, M Padma et al., Cutaneous leukocytoclastic
vasculitis as the first manifestation
of malignant syphilis coinfected with human
immunodeficiency virus, J Cutan Pathol, 46(5),
2019, p. 393-395.
[6] WC Tan, CK Ong, SC Kang et al., Two years
review of cutaneous adverse drug reaction from
first line anti-tuberculous drugs, Med J Malaysia,
62(2), 2007, p. 143-6.
[7] WE Parish, EL Rhodes, Bacterial antigens and
aggregated gamma globulin in the lesions of
nodular vasculitis, Br J Dermatol, 79(3), 1967,
p. 131-47.
[8] M Carvalho, RL Dominoni, D Senchechen et al.,
Cutaneous leukocytoclastic vasculitis accompanied
by pulmonary tuberculosis, J Bras Pneumol, 34(9),
2008, p. 745-8.
[9] NM Johnson, MW McNicol, EJ Burton-Kee et
al., Circulating immune complexes in tuberculosis,
Thorax, 36(8), 1981, p. 610-7.
[10] CH Chan, YW Chong, AJ Sun et al., Cutaneous
vasculitis associated with tuberculosis and its
treatment, Tubercle, 71(4), 1990, p. 297-300.
[11] JH Kim, JI Moon, JE Kim et al., Cutaneous
leukocytoclastic vasculitis due to anti-tuberculosis
medications, rifampin and pyrazinamide, Allergy
Asthma Immunol Res, 2(1), 2010, p. 55-8.
[12] Kumutnart C, Wanjarus R, Kunlawat T, Annular
leukocytoclastic vasculitis associated with anti-tuberculosis
medications: A case report, Journal of Medical Case
Reports, 7(1), 2013, p. 34.
[13] T Schaberg, K Rebhan, H Lode, Risk factors for
side-effects of isoniazid, rifampin and pyrazinamide
in patients hospitalized for pulmonary
tuberculosis, Eur Respir J, 9(10), 1996, p. 2026-30.